Understanding how ATR signaling affects cancer treatment effectiveness
Uncovering ATR signaling networks underlying chemotherapeutic synergies
['FUNDING_FELLOWSHIP'] · CORNELL UNIVERSITY · NIH-10913308
This study is looking at how a special protein called ATR can help make certain cancer treatments work better together, especially for patients whose cancers don’t respond well to regular therapies, with the hope of finding new ways to improve their treatment.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CORNELL UNIVERSITY (nih funded) |
| Locations | 1 site (ITHACA, UNITED STATES) |
| Trial ID | NIH-10913308 on ClinicalTrials.gov |
What this research studies
This research investigates the role of ATR, a key protein involved in DNA damage response, in enhancing the effectiveness of certain cancer treatments. By using advanced techniques like mass spectrometry, the study aims to uncover the complex signaling networks activated in cancer cells when treated with specific chemotherapeutic agents. The goal is to identify how these treatments can work better together, particularly for cancers that show resistance to standard therapies. Patients may benefit from insights that could lead to more effective combination therapies for their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are known to be treated with ATR inhibitors and experience replication stress, such as colon cancer.
Not a fit: Patients with cancers that do not involve ATR signaling or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies that enhance the effectiveness of existing therapies.
How similar studies have performed: Other research has shown promising results in targeting ATR signaling in cancer therapy, indicating that this approach has potential for success.
Where this research is happening
ITHACA, UNITED STATES
- CORNELL UNIVERSITY — ITHACA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COMSTOCK, WILLIAM — CORNELL UNIVERSITY
- Study coordinator: COMSTOCK, WILLIAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Genes, Cancer Treatment, Cancer cell line, Cancer-Promoting Gene, Cancers